8-K: Exagen Inc. Reports Record Revenue and Improved Margins in Full-Year 2023 Results

Exagen Inc. announced record full-year revenue of $52.5 million and a significant increase in gross margin, alongside a reduction in net loss and operating expenses for 2023.

Summary

• Exagen Inc. reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company achieved record total revenue of $52.5 million for the full year and $13.8 million for the fourth quarter.
• A record 137,650 AVISE CTD tests were performed in 2023, including 30,438 in the fourth quarter, bringing the total to over 900,000 since launch.
• The average selling price (ASP) for AVISE CTD tests increased by $51 over the year to $336.
• Gross margin was 56% for the full year and 59% for the fourth quarter.
• The company reported a net loss of $23.7 million for the full year and $5.6 million for the fourth quarter.
• Adjusted EBITDA was $(17.1) million for the full year and $(3.9) million for the fourth quarter.
• Exagen ended the year with a cash balance of $36.5 million.
• The company is providing full-year 2024 revenue guidance of approximately $54 million and first quarter 2024 revenue guidance of $13.0 million to $13.5 million.
• Exagen believes its adjusted EBITDA for 2024 will be better than negative $20 million and that its existing cash is adequate to meet anticipated cash requirements into 2026.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue growth, improved margins, and reduced losses. However, the company is still not profitable and faces some risks, which tempers the overall sentiment.

Positives

• Exagen achieved record revenue for the full year 2023.
• The number of AVISE CTD tests performed reached a record high.
• The average selling price of tests increased significantly.
• Gross margins improved both for the full year and the fourth quarter.
• Operating expenses were reduced year-over-year.
• The net loss was significantly reduced compared to the previous year.
• Adjusted EBITDA showed substantial improvement year-over-year.
• The company has a solid cash balance.
• Exagen provided positive revenue guidance for 2024.
• The company believes its current cash is sufficient to meet needs into 2026.

Negatives

• The company still reported a net loss for both the full year and the fourth quarter.
• Adjusted EBITDA remains negative for both the full year and the fourth quarter.

Risks

• The company faces risks related to reimbursement and coverage decisions from Medicare and third-party payors.
• Delays in interactions with regulatory authorities and clinical trials could impact the business.
• The company's commercial success depends on market acceptance of its testing products.
• Failure to obtain and maintain intellectual property protection could harm the business.
• Regulatory developments could negatively affect the company's operations.

Future Outlook

Exagen is providing full-year 2024 revenue guidance of approximately $54 million and first quarter 2024 revenue guidance of $13.0 million to $13.5 million. The company believes its adjusted EBITDA for 2024 will be better than negative $20 million and that its existing cash is adequate to meet anticipated cash requirements into 2026.

Management Comments

• John Aballi, President and Chief Executive Officer, stated that the company is steering towards profitability with a focus on increasing ASP and reducing expenses.
• He also mentioned that the progress made in the past year has significantly bolstered the health of the organization.
• He expressed confidence that the best is yet to come for Exagen.

Industry Context

Exagen operates in the autoimmune testing market, which is a growing sector within the broader diagnostics industry. The company's focus on improving ASP and reducing expenses aligns with industry trends towards profitability and efficiency. The company's growth in test volumes and revenue indicates a positive market reception for its products.

Comparison to Industry Standards

• Exagen's revenue growth of approximately 15% year-over-year is a positive sign, but it is important to compare this to other diagnostic companies in the autoimmune space such as Myriad Genetics (MYGN) or companies focused on similar testing methodologies like Exact Sciences (EXAS).
• The improvement in gross margin from 46.9% to 56.1% year-over-year is a significant achievement, but it is important to compare this to the gross margins of other diagnostic companies, which can range from 50% to 70% depending on the type of testing and business model.
• The reduction in operating expenses is a positive trend, but it is important to assess whether these reductions are sustainable and not impacting the company's growth potential.
• The company's adjusted EBITDA is still negative, which is not uncommon for growth-stage companies in the diagnostics sector, but it is important to monitor the trend and compare it to peers.
• The cash balance of $36.5 million is adequate for the near term, but it is important to assess the company's cash burn rate and potential need for future capital raises.

Stakeholder Impact

• Shareholders will likely view the improved financial results positively.
• Employees may be encouraged by the company's progress towards profitability.
• Clinicians and patients will benefit from the company's continued focus on providing quality testing solutions.
• Suppliers and creditors may have increased confidence in the company's financial stability.

Next Steps

• The company will continue to focus on increasing ASP and reducing expenses.
• Exagen will work towards achieving its 2024 revenue and adjusted EBITDA targets.
• The company will continue to serve clinicians and patients with its testing solutions.

Key Dates

Keywords

Autoimmune Testing, AVISE CTD, Revenue, Gross Margin, EBITDA, Financial Results, Diagnostics, Healthcare, Medical Testing, Biotechnology